

WEST[Help](#)[Logout](#)[Interrupt](#)[Main Menu](#)[Search Form](#)[Posting Counts](#)[Show S Numbers](#)[Edit S Numbers](#)[Preferences](#)**Search Results -**

Term	Documents
CD40L.USPT,PGPB.	97
CD40LS.USPT,PGPB.	2
CD40.USPT,PGPB.	448
CD40S	0
LIGAND.USPT,PGPB.	31229
LIGANDS.USPT,PGPB.	25519
GP39.USPT,PGPB.	69
GP39S	0
CD20.USPT,PGPB.	445
CD20S	0
((CD40L OR CD40 ADJ LIGAND OR GP39) SAME (CD20 OR RITUXAN) SAME (LEUKEMIA\$ OR LYMPHOMA\$ OR HODGKIN\$)).USPT,PGPB.	1

[There are more results than shown above. Click here to view the entire set.](#)

Database:

US Patents Full-Text Database
US Pre-Grant Publication Full-Text Database
JPO Abstracts Database
EPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Refine Search:

(cd40L or cd40 adj ligand or gp39) same
(cd20 or rituxan) same (leukemia\$ or
lymphoma\$ or hodgkin\$)

[Clear](#)**Search History****Today's Date: 7/1/2001**

7/2/01

<u>DB Name</u>	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u>
USPT,PGPB	(cd40L or cd40 adj ligand or gp39) same (cd20 or rituxan) same (leukemia\$ or lymphoma\$ or hodgkin\$)	1	<u>L11</u>
USPT,PGPB	(cd40L or cd40 adj ligand or gp39) same (antibod\$)same (131)	1	<u>L10</u>
USPT,PGPB	idec adj 131	0	<u>L9</u>
USPT,PGPB	(cd40L or cd40 adj ligand) same (leukemia\$ or lymphoma\$ or hodgkin\$)	24	<u>L8</u>
USPT,PGPB	(cd20) same (rituxan or b1) same (leukemia\$ or lymphoma\$ or hodgkin\$)	16	<u>L7</u>
USPT,PGPB	(cd20) same (rituxan or b1)	76	<u>L6</u>
USPT,PGPB	l1 and (cd20) and (leukemia\$ or lymphoma\$) and (cd40L or cd40 adj ligand)	1	<u>L5</u>
USPT,PGPB	l1 and (cd20) and (leukemia\$ or lymphoma\$)	10	<u>L4</u>
USPT,PGPB	l1 and (cd20)	10	<u>L3</u>
USPT,PGPB	l1 and (rituxan)	0	<u>L2</u>
USPT,PGPB	hanna-nabil\$	22	<u>L1</u>

745)

***Dail and Snda Telegraph (London) Paper (File 756)
***The Mirror Grop Pblication (United Kingdom) (File 757)
***Reter Bine Inight (File 759)

UPDATING RESUMED

***Delphe Eropean Bine (File 481)
***Extel Financial Card from Primark (File 500)
***Book In Print (File 470)
***Extel New Card from Primark (File 501)

RELOADED

***Kompa Middle Eat/Africa/Mediterranean (File 585)
***Kompa Aia/Pacific (File 592)
***Kompa Central/Eatern Erope (File 593)
***Kompa Canada (File 594)

FILES REMOVED

***EconBae (File 565)

New pricing trctre for Pharmaproject (File 128/928) from
April 1, 2001. Check Help New128 or Help New928 for frther
information.

>>>Get immediate new with Dialog' First Release
new erice. First Release pdate major newwire
databae within 15 minte of tranmlion oer the
wire. First Release proide flil Dialog earchabilit
and flil-text featre. To earch First Release file in
OneSearch impl BEGIN FIRST for coerage from Dialog'
broad pectrm of new wire.

>>> Enter BEGIN HOMEBASE for Dialog Annoucement <<<
>>> of new databae, price change, etc. <<<

File 1:ERIC 1966-2001/Jn 05
(c) format onl 2001 The Dialog Corporation

Ddialog

Set	Items	Description
-----	-------	-------------

? b 410

>>>'IALOG' not recognized as set or accession number
? set hi ;set hi

01jul01 08:16:20 User208760 Session D1872.1
\$0.42 0.119 DialUnits File1
\$0.42 Estimated cost File1
\$0.05 TYMNET
\$0.47 Estimated cost this search
\$0.47 Estimated total session cost 0.119 DialUnits

File 410:Chronolog(R) 1981-2001/May
(c) 2001 The Dialog Corporation

Set	Items	Description
-----	-------	-------------

?
HIGHLIGHT set on as ''
HIGHLIGHT set on as ''
? begin 5,73,155,399

01jul01 08:16:28 User208760 Session D1872.2
\$0.00 0.056 DialUnits File410
\$0.00 Estimated cost File410
\$0.01 TYMNET
\$0.01 Estimated cost this search
\$0.48 Estimated total session cost 0.175 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 5:Biosis Previews(R) 1969-2001/Jun W4
(c) 2001 BIOSIS

File 73:EMBASE 1974-2001/Jun W4
(c) 2001 Elsevier Science B.V.

*File 73: For information about Explode feature please
see Help News73.

File 155:MEDLINE(R) 1966-2001/Jul W2
(c) format only 2001 Dialog Corporation

*File 155: This file has been reloaded. Accession numbers have changed.
Please see Help News155 for further details.

File 399:CA SEARCH(R) 1967-2001/UD=13501
(c) 2001 AMERICAN CHEMICAL SOCIETY

*File 399: Use is subject to the terms of your user/customer agreement.
RANK charge added; see HELP RATES 399.

Set Items Description

? e au=hanna nabil

Ref	Items	Index-term
E1	6	AU=HANNA N.S.
E2	1	AU=HANNA NA
E3	23	*AU=HANNA NABIL
E4	1	AU=HANNA NADER
E5	9	AU=HANNA NADER N
E6	4	AU=HANNA NAEEM
E7	5	AU=HANNA NAEEM B
E8	3	AU=HANNA NANCY
E9	1	AU=HANNA NASHAT F
E10	1	AU=HANNA NAWAL EBIED
E11	6	AU=HANNA NAZEEH
E12	1	AU=HANNA NAZEEH H

Enter P or PAGE for more

? s e3

S1 23 AU="HANNA NABIL"
? rd s1

...completed examining records
S2 23 RD S1 (unique items)
? t s2/3/all

2/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

13032667 BIOSIS NO.: 200100239816
Recombinant anti-CD4 antibodies for human therapy.
AUTHOR: Hanna Nabil(a); Newman Roland Anthony; Reff Mitchell Elliot

AUTHOR ADDRESS: (a)Olivenhain, CA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1239 (4):pNo Pagination Oct. 24, 2000
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

2/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12995073 BIOSIS NO.: 200100202222
Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies.
AUTHOR: Anderson Darrell R(a); Brams Peter; **Hanna Nabil**; Shestowsky William S; Heard Cheryl
AUTHOR ADDRESS: (a)Escondido, CA**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1238 (1):pNo Pagination Sep. 5, 2000
MEDIUM: e-file
ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

2/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12940410 BIOSIS NO.: 200100147559
Modification of the Fc region of a Primatized IgG antibody to human CD4, retains its ability to modulate CD4 receptors but does not deplete CD4+ T cells in chimpanzees.
AUTHOR: Newman Roland(a); Hariharan Kandasamy; Reff Mitchell; Anderson Darrel R; Braslawsky Gary; Santoro Denise; **Hanna Nabil**; Bugelski Peter J; Brigham-Burke Michael; Crysler Carl; Gagnon Robert C; Dal Monte Paul; Doyle Michael L; Hensley Preston C; Reddy Manjula P; Sweet Raymond W; Trunch Alemseged
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corporation, 11011 Torreyana Road, San Diego, CA, 92121**USA
JOURNAL: Clinical Immunology (Orlando) 98 (2):p164-174 February, 2001
MEDIUM: print
ISSN: 1521-6616
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

2/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12538774 BIOSIS NO.: 200000292276
Humanized antibodies to human gp39, compositions containing thereof.
AUTHOR: Black Ameli; **Hanna Nabil**; Padlan Eduardo A(a); Newman Roland A
AUTHOR ADDRESS: (a)Kensington, MD**USA
JOURNAL: Official Gazette of the United States Patent and Trademark Office
Patents 1229 (2):pNo pagination Dec. 14, 1999
MEDIUM: e-file.

ISSN: 0098-1133
DOCUMENT TYPE: Patent
RECORD TYPE: Abstract
LANGUAGE: English

2/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12491486 BIOSIS NO.: 200000244988
Rituximab-mediated growth regulation and drug sensitization of B lymphoma:
Pivotal role of IL-10.
AUTHOR: Alas Steve(a); Emmanouilides Christos; **Hanna Nabil**; Bonavida
Benjamin
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corp, San Diego, CA**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual
Meeting (41):p288 March, 2000
CONFERENCE/MEETING: 91st Annual Meeting of the American Association for
Cancer Research. San Francisco, California, USA April 01-05, 2000
ISSN: 0197-016X
RECORD TYPE: Citation
LANGUAGE: English
SUMMARY LANGUAGE: English

2/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12284780 BIOSIS NO.: 200000042647
Enhanced effector functions of dimeric forms of IDEC-C2B8 (rituximab).
AUTHOR: Jiang LiYing(a); Pan Li-Zhen(a); Hariharan Kandasamy(a); Chinn Paul
(a); Barnett Richard(a); Braslawsky Gary(a); Leonard John E(a); **Hanna
Nabil**(a); Anderson Darrell R(a)
AUTHOR ADDRESS: (a)Research and Preclinical Development, IDEC
Pharmaceuticals Corp., San Diego, CA**USA
JOURNAL: Blood 94 (10 SUPPL. 1 PART 1):p86a Nov. 15, 1999
CONFERENCE/MEETING: Forty-first Annual Meeting of the American Society of
Hematology New Orleans, Louisiana, USA December 3-7, 1999
SPONSOR: The American Society of Hematology
ISSN: 0006-4971
RECORD TYPE: Citation
LANGUAGE: English

2/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

12271987 BIOSIS NO.: 200000025489
Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for
treatment of non-Hodgkin's lymphoma.
AUTHOR: Chinn Paul C(a); Leonard John E; Rosenberg Jay; **Hanna Nabil**;
Anderson Darrell R
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Inc., 11011 Torreyana Road, San
Diego, CA, 92121**USA
JOURNAL: International Journal of Oncology 15 (5):p1017-1025 Nov., 1999
ISSN: 1019-6439
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English
SUMMARY LANGUAGE: English

2/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11995244 BIOSIS NO.: 199900275763
In vitro suppression of IgE synthesis by a primatized monoclonal antibody
(mab) against human CD23 antigen.
AUTHOR: Li Yan-Ping; Kloetzer William; Nakamura Takehiko(a); Chen Agnes;
Brams Peter; Hariharan Kandasamy; Chamat Soulaïma; Cao Xianjun; LaBarre
Michael; Chinn Paul; Morena Ron; Shestowsky William; **Hanna Nabil**;
Reff Mitchell
AUTHOR ADDRESS: (a)Seikagaku Corp., Tokyo**Japan
JOURNAL: FASEB Journal 13 (5 PART 2):pA989 March 15, 1999
CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists
on Experimental Biology 99 Washington, D.C., USA April 17-21, 1999
SPONSOR: Federation of American Societies for Experimental Biology
ISSN: 0892-6638
RECORD TYPE: Citation
LANGUAGE: English

2/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11995242 BIOSIS NO.: 199900275761
A humanized anti-human CD154 monoclonal antibody blocks CD154-CD40 mediated
human B cell activation.
AUTHOR: Chambers-Slater Karen(a); Brams Peter(a); Black Amelia(a); Padlan
Eduardo A; Shestowsky William(a); Shearin Tracey(a); Nguyen Mai-Lan(a);
Noelle Randolph J; **Hanna Nabil**(a); Newman Roland(a)
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corporation, 11011 Torreyana Road,
San Diego, CA, 92121**USA
JOURNAL: FASEB Journal 13 (5 PART 2):pA988 March 15, 1999
CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists
on Experimental Biology 99 Washington, D.C., USA April 17-21, 1999
SPONSOR: Federation of American Societies for Experimental Biology
ISSN: 0892-6638
RECORD TYPE: Citation
LANGUAGE: English

2/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11995118 BIOSIS NO.: 199900275637
In vitro immunological and functional properties of primate/human chimeric
monoclonal (PRIMATIZED(R)) antibodies to human CD80.
AUTHOR: Shestowsky William(a); Brams Peter(a); Pan Li-Zhen(a); Nguyen
Mai-Lan(a); Chambers-Slater Karen(a); Franco Luis(a); **Hanna Nabil**
(a); Anderson Darrell(a)
AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corporation, 11011 Torreyana Road,
San Diego, CA, 92121**USA
JOURNAL: FASEB Journal 13 (5 PART 2):pA953 March 15, 1999
CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists
on Experimental Biology 99 Washington, D.C., USA April 17-21, 1999
SPONSOR: Federation of American Societies for Experimental Biology
ISSN: 0892-6638
RECORD TYPE: Citation
LANGUAGE: English

2/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

11994995 BIOSIS NO.: 199900275514

Macrophage migration inhibitory factor (MIF) influence on disease progression in lupus nephritis-prone mice.

AUTHOR: Kloetzer William; Li Yan-Ping; Chen Agnes; Carlisle Bill; Strahl Dana; Metz Christine(a); Bucala Richard(a); **Hanna Nabil**

AUTHOR ADDRESS: (a)Picower Institute, Manhasset, NY**USA

JOURNAL: FASEB Journal 13 (5 PART 2):pA658 March 15, 1999

CONFERENCE/MEETING: Annual Meeting of the Professional Research Scientists on Experimental Biology 99 Washington, D.C., USA April 17-21, 1999

SPONSOR: Federation of American Societies for Experimental Biology

ISSN: 0892-6638

RECORD TYPE: Citation

LANGUAGE: English

2/3/12 (Item 12 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

11956182 BIOSIS NO.: 199900202291

IDEC-Y2B8: A 90Y-labeled anti-CD20 monoclonal antibody conjugated to MX-DTPA, a high-affinity chelator for yttrium.

AUTHOR: Chinn Paul C; Leonard John E; Rosenberg Jay; **Hanna Nabil**; Anderson Darrell R

AUTHOR ADDRESS: IDEC Pharmaceuticals Corp., San Diego, CA**USA

JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 40p574 March, 1999

CONFERENCE/MEETING: 90th Annual Meeting of the American Association for Cancer Research Philadelphia, Pennsylvania, USA April 10-14, 1999

SPONSOR: American Association for Cancer Research

ISSN: 0197-016X

RECORD TYPE: Citation

LANGUAGE: English

2/3/13 (Item 13 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

11862889 BIOSIS NO.: 199900108998

Chimeric anti-CD20 (C2B8)-mediated sensitization of B cell lymphoma to cytotoxic agents: Role of C2B8 in regulation endogenous IL-10 and oncogenes.

AUTHOR: Alas Steve(a); **Hanna Nabil**; Emmanouilides Christos; Bonavida Benjamin

AUTHOR ADDRESS: (a)Dep. Microbiol. Immunol., UCLA Sch. Med., 10833 Le Conte Ave., Los Angeles, CA 90095-1747**USA

JOURNAL: Blood 92 (10 SUPPL. 1 PART 1-2):p601A Nov. 15, 1998

CONFERENCE/MEETING: 40th Annual Meeting of the American Society of Hematology Miami Beach, Florida, USA December 4-8, 1998

SPONSOR: The American Society of Hematology

ISSN: 0006-4971

RECORD TYPE: Citation

LANGUAGE: English

2/3/14 (Item 14 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

11592218 BIOSIS NO.: 199800372914

Development and application of PROVAX adjuvant formulation for subunit cancer vaccines.

AUTHOR: Hariharan Kandasamy(a); **Hanna Nabil**
AUTHOR ADDRESS: (a)IDEC Pharm. Corp., 11011 Torreyanna Road, San Diego, CA
92121**USA
JOURNAL: Advanced Drug Delivery Reviews 32 (3):p187-197 July 6, 1998
ISSN: 0169-409X
DOCUMENT TYPE: Literature Review
RECORD TYPE: Citation
LANGUAGE: English

2/3/15 (Item 15 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11525029 BIOSIS NO.: 199800306361
Tumor regression in mice following vaccination with human papillomavirus E7
recombinant protein in PROVAX.
AUTHOR: Hariharan Kandasamy(a); Braslawsky Gary; Barnett Richard S;
Berquist Lisa G; Huynh Tri; **Hanna Nabil**; Black Amelia
AUTHOR ADDRESS: (a)IDEC Pharm. Corp., 11011 Torreyana Rd., San Diego, CA
92121**USA
JOURNAL: International Journal of Oncology 12 (6):p1229-1235 June, 1998
ISSN: 1019-6439
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/16 (Item 16 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11217379 BIOSIS NO.: 199799838524
Antigen formulation for recombinant cancer vaccines.
AUTHOR: **Hanna Nabil**; Black Amelia; Hariharan Kandasamy
AUTHOR ADDRESS: IDEC Pharm. Corp., 11011 Torreyana Rd., San Diego, CA
92121**USA
JOURNAL: International Journal of Oncology 11 (SUPPL.):p924 1997
CONFERENCE/MEETING: 2nd World Congress on Advances in Oncology Athens,
Greece October 16-18, 1997
ISSN: 1019-6439
RECORD TYPE: Citation
LANGUAGE: English

2/3/17 (Item 17 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11088852 BIOSIS NO.: 199799709997
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell
lymphoma cell line to cell killing by cytotoxic drugs.
AUTHOR: Demidem Aicha; Lam Tammy; Alas Steve; Hariharan Kandasamy; **Hanna
Nabil**; Bonavida Benjamin(a)
AUTHOR ADDRESS: (a)Dep. Microbiol. Immunol., UCLA Sch. Med., 10833 Le Conte
Ave., Los Angeles, CA 90095-1747**USA
JOURNAL: Cancer Biotherapy & Radiopharmaceuticals 12 (3):p177-186 1997
ISSN: 1084-9785
RECORD TYPE: Abstract
LANGUAGE: English

2/3/18 (Item 18 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

10990359 BIOSIS NO.: 199799611504

A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: In vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4.

AUTHOR: Anderson Darrell; Chambers Karen; **Hanna Nabil**; Leonard John; Reff Mitchel; Newman Roland(a); Baldoni John; Dunleavy Donna; Reddy Manjula; Sweet Raymond; Truneh Alemseged

AUTHOR ADDRESS: (a)IDEC Pharm. Corp., 11011 Torreyana Rd., San Diego, CA 92121**USA

JOURNAL: Clinical Immunology and Immunopathology 84 (1):p73-84 1997

ISSN: 0090-1229

RECORD TYPE: Abstract

LANGUAGE: English

2/3/19 (Item 19 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

10411351 BIOSIS NO.: 199699032496

Two neutralizing human monoclonal antibodies, specific for fusion protein of respiratory syncytial virus, isolated from hu-SCID mice.

AUTHOR: Chamat Soulaïma(a); Walsh Edward E; **Hanna Nabil**; Anderson Darrell; Brams Peter

AUTHOR ADDRESS: (a)American Univ. Beirut, Dep. Microbiol. Immunol., Sch. Med., 850 Third Ave., New York, NY 10022**USA

JOURNAL: FASEB Journal 10 (6):pA1465 1996

CONFERENCE/MEETING: Joint Meeting of the American Society for Biochemistry and Molecular Biology, the American Society for Investigative Pathology and the American Association of Immunologists New Orleans, Louisiana, USA June 2-6, 1996

ISSN: 0892-6638

RECORD TYPE: Citation

LANGUAGE: English

2/3/20 (Item 20 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

10155228 BIOSIS NO.: 199698610146

Induction of T-cell immunity against Ras oncoproteins by soluble protein or Ras-expressing Escherichia coli.

AUTHOR: Fenton Robert G(a); Keller Christopher J; **Hanna Nabil**; Taub Dennis D

AUTHOR ADDRESS: (a)National Cancer Inst.-Frederick Cancer Research Development Center, PO Box B, Bldg. 567, Rm. 207**USA

JOURNAL: Journal of the National Cancer Institute (Bethesda) 87 (24):p 1853-1861 1995

ISSN: 0027-8874

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

2/3/21 (Item 21 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2001 BIOSIS. All rts. reserv.

10000065 BIOSIS NO.: 199598454983

The Induction of Cytotoxic T Cells and Tumor Regression by Soluble antigen Formulation.

AUTHOR: Hariharan Kandasamy(a); Braslawsky Gary; Black Amelia; Raychaudhuri Syamal; **Hanna Nabil**

AUTHOR ADDRESS: (a)IDEC Pharmaceuticals Corporation, 11011 Torreyana Road,
San Diego, CA 92121**USA
JOURNAL: Cancer Research 55 (16):p3486-3489 1995
ISSN: 0008-5472
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/22 (Item 22 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

09117910 BIOSIS NO.: 199497126280
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody
to CD20.
AUTHOR: Reff Mitchell E; Carner Kristin; Chambers Karen S; Chinn Paul C;
Leonard John E; Raab Ron; Newman Roland A; **Hanna Nabil**; Anderson
Darrell R(a)
AUTHOR ADDRESS: (a)IDEC Pharm. Corp., 11011 Torreyana Rd., San Diego, CA
92121**USA
JOURNAL: Blood 83 (2):p435-445 1994
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

2/3/23 (Item 23 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

08620920 BIOSIS NO.: 199345038995
Depletion of B cells in vitro by a chimeric mouse human monoclonal antibody
to CD20.
AUTHOR: Reff Mitchell; Leonard John; Newman Roland; **Hanna Nabil**;
Anderson Darrell
AUTHOR ADDRESS: IDEC Pharmaceuticals Corp., La Jolla, CA 92037**USA
JOURNAL: Journal of Cellular Biochemistry Supplement 0 (17 PART E):p260
1993
CONFERENCE/MEETING: Keystone Symposium on B and T Cell Lymphomas Copper
Mountain, Colorado, USA April 17-23, 1993
ISSN: 0733-1959
RECORD TYPE: Citation
LANGUAGE: English
? s (cd40L or cd40(w)ligand or gp39) (30n)(cd20 or rituxan or b1) and
(leukemia? or lymphoma? or hodgkin?)

	3086	CD40L
	12123	CD40
	282653	LIGAND
	5287	CD40(W)LIGAND
	507	GP39
	6803	CD20
	243	RITUXAN
	45959	B1
	44	((CD40L OR CD40(W)LIGAND) OR GP39) (30N) ((CD20 OR RITUXAN) OR B1)
	458402	LEUKEMIA?
	248418	LYMPHOMA?
	108973	HODGKIN?
S3	12	(CD40L OR CD40(W)LIGAND OR GP39) (30N) (CD20 OR RITUXAN OR B1) AND (LEUKEMIA? OR LYMPHOMA? OR HODGKIN?)

? rd s3

...completed examining records
S4 8 RD S3 (unique items)
? t s4/7/all

4/7/1 (Item 1 from file: 5)
DIALOG(R)File 5:BIOSIS Previews(R)
(c) 2001 BIOSIS. All rts. reserv.

11447606 BIOSIS NO.: 199800228938
Chronic lymphocytic **leukemia** B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity.
AUTHOR: Schattner Elaine J(a); Mascarenhas John; Reyfman Inna; Koshy Mary; Woo Caroline; Friedman Steven M; Crow Mary K
AUTHOR ADDRESS: (a)Room C-640, Cornell Univ. Med. Coll., 1300 York Ave., New York, NY 10021**USA
JOURNAL: Blood 91 (8):p2689-2697 April 15, 1998
ISSN: 0006-4971
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Chronic lymphocytic **leukemia** (CLL) is characterized by a clonal expansion of CD5!+ B cells in the peripheral blood. Associated immune aberrations include abnormal Th-cell function and pathogenic autoantibodies. Under most circumstances, CLL B cells do not proliferate in culture and express a limited repertoire of surface antigens, including CD19, **CD20**, CD23, CD27, CD40, and CD70. In this report, we demonstrate that freshly isolated B cells from a subset of CLL cases constitutively express **CD40 ligand** (**CD40L**, CD154), a member of the tumor necrosis factor family which is normally expressed by activated CD4!+ T cells and mediates T-cell-dependent B-cell proliferation and antibody production. The degree of CD40L expression varied considerably among the CLL cases examined. CD40L was detected in purified CLL B cells by immunofluorescence flow cytometry, by RT-PCR, and by immunoprecipitation. To demonstrate that CD40L in the CLL B cells is functional, we used irradiated CLL cells to stimulate IgG production by target, nonmalignant B cells in coculture. The CLL B cells induced IgG production by normal B cells to a similar degree as did purified T cells in a process which was partially inhibited by monoclonal antibody to CD40L. This is one of the first reports of CD40L expression in a B-cell tumor. The data suggest that CD40L in the tumor cells may be a factor in the generation of pathologic antibodies by normal B cells in some patients with CLL.

4/7/2 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

11040677 EMBASE No: 2001073341
Overview of idiopathic thrombocytopenic purpura: New approach to refractory patients
Bussel J.B.
Dr. J.B. Bussel, Weill Med. College of Cornell Univ., Department of Pediatrics, Div. of Pediatric Hematol./Oncology, 525 E 68th St, New York, NY 10021 United States
Seminars in Oncology (SEMIN. ONCOL.) (United States) 2000, 27/6
SUPPL. 12 (91-98)
CODEN: SOLGA ISSN: 0093-7754
DOCUMENT TYPE: Journal ; Conference Paper
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 25

Idiopathic thrombocytopenic purpura is a disorder in which autoantibodies

are made to platelets, resulting in accelerated platelet destruction. The diagnosis may be made in outpatients who are previously well or in patients with multiple medical conditions and medications. There are no unequivocal ways to distinguish immune thrombocytopenias from other thrombocytopenias, even with state-of-the-art tests including antiplatelet antibodies, thrombopoietin, glycocalicin, and platelet reticulocyte counts. Clinical evaluation includes ruling out a systemic process such as a viral infection or **leukemia**. Treatment of idiopathic thrombocytopenic purpura should be individualized. Substantial platelet increases are seen in more than 50% of patients who receive intravenous IgG, intravenous anti-D, steroids, or splenectomy. Two additional agents showing promising clinical trial experience are anti-**CD40 ligand** and rituximab (**Rituxan**; Genentech, Inc, South San Francisco, CA and IDEC Pharmaceutical Corporation, San Diego, CA). Copyright (c) 2000 by W.B. Saunders Company.

4/7/3 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

07642174 EMBASE No: 1999127877

Expression of CD40/CD40 ligand and Bcl-2 family proteins in labial salivary glands of patients with Sjogren's syndrome

Nakamura H.; Kawakami A.; Tominaga M.; Migita K.; Kawabe Y.; Nakamura T.; Eguchi K.

Prof. K. Eguchi, First Dept. of Internal Medicine, Nagasaki University Sch. of Medicine, 1-7-1 Sakamoto, Nagasaki City, Nagasaki 852-8501 Japan
Laboratory Investigation (LAB. INVEST.) (United States) 1999, 79/3 (261-269)

CODEN: LAINA ISSN: 0023-6837

DOCUMENT TYPE: Journal; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 29

Lymphocytes infiltrating the Salivary glands of patients with Sjogren's syndrome (SS) are activated and resist apoptosis. We determined the role of interactions between CD40 and CD40 ligand (CD40L) in these infiltrating lymphocytes on B-cell differentiation and expression of Bcl-2 family proteins. Ten human T-cell **leukemia/lymphoma** virus-I (HTLV-I)-seronegative and eight HTLV-I-seropositive SS patients were examined in the present study: Immunohistochemistry was performed to examine the expression of CD3, **CD20**, PCA-1, CD40, **CD40L**, Bcl-2, Bax, and Bcl-x on T and B lymphocytes infiltrating labial salivary glands of SS patients. We also examined expression of CD40 and **CD40L** on peripheral blood lymphocytes of the same patients by using flow cytometry. CD40L was not expressed on peripheral blood lymphocytes of SS patients. Peripheral blood B cells but not T cells expressed CD40. In contrast, >50% of mononuclear cells, including T and B cells infiltrating the glands, expressed CD40. In addition, a clear expression of CD40L in both infiltrating T cells and B cells, and that of PCA-1, was also demonstrated. Surprisingly, the expression of Bcl-2 and Bcl-x was colocalized with that of CD40 determined by mirror section technique. Bcl-x was also abundantly expressed on infiltrating mononuclear cells, but, Bax expression was relatively less than that of Bcl-2 or Bcl-x. The expression of the above molecules was not different between HTLV-I-seronegative and HTLV-I-seropositive SS patients. Our results indicate that CD40/CD40L pathways could be augmented in salivary glands of SS patients, inducing B-cell differentiation to PCA-1+ plasma cells. Immunohistochemical analysis also suggests that signaling through CD40 by means of CD40L increases the expression of Bcl-2 as well as Bcl-x in infiltrating lymphocytes, providing the resistance against apoptosis. Our findings were commonly observed in SS patients irrespective of HTLV-I seropositivity.

4/7/4 (Item 3 from file: 73)

07557481 EMBASE No: 1999053020
CD5 B cells and B-cell malignancies
Lydyard P.M.; Jewell A.P.; Jamin C.; Youinou P.Y.
Dr. P.M. Lydyard, Department of Immunology, UCL Medical School, London
United Kingdom
Current Opinion in Hematology (CURR. OPIN. HEMATOL.) (United States)
1999, 6/1 (30-36)
CODEN: COHEF ISSN: 1065-6251
DOCUMENT TYPE: Journal; Review
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 107

Over the past year, progress has been made in understanding of the physiology and disease associations of CD5+ (B1) B cells, although their exact role in pathogenesis remains unclear. Earlier studies on the negative function of CD5 within the B-cell receptor complex have been substantiated, and it seems likely that soon the signaling pathways used by this coreceptor will be elucidated. Progress in diagnosis, physiology, and etiopathogenesis of CD5+ malignancies has been made, particularly in B-cell chronic lymphocytic **leukemia**. The low-level expression of surface immunoglobulin has been explained by the mutations that occur in the associated CD79b. Two new potential tumor-suppressor genes have been identified in the hot spot of chromosome 13q, which provides an exciting step forward in understanding of the etiopathogenesis of some B-cell chronic lymphocytic **leukemia**. Activated signal transducers for activation of transcription factors molecules have been shown to be phosphorylated on different amino acids in B1 and chronic lymphocytic **leukemia** tumors, although the significance of this is, as yet, unclear. Finally, aberrant expression of **CD40L** by chronic lymphocytic **leukemia** T cells may contribute to the immunodeficiency that develops in these patients.

4/7/5 (Item 4 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2001 Elsevier Science B.V. All rts. reserv.

07223207 EMBASE No: 1998099436
The A-Myb transcription factor is a marker of centroblasts in vivo
Golay J.; Broccoli V.; Lamorte G.; Bifulco C.; Parravicini C.; Pizzey A.;
Thomas N.S.B.; Delia D.; Ferrauti P.; Vitolo D.; Introna M.
Dr. J. Golay, Ist. Ricerche Farmacol. 'M. Negri', via Eritrea 62, 20157
Milano Italy
AUTHOR EMAIL: Martino@irfmm.mnegri.it
Journal of Immunology (J. IMMUNOL.) (United States) 15 MAR 1998, 160/6
(2786-2793)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article
LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH
NUMBER OF REFERENCES: 48

The A-Myb transcription factor is structurally related to the c-myb proto-oncogene and is involved in the control of proliferation and/or differentiation of mature B lymphocytes. We have shown previously by PCR analysis that A-myb is preferentially expressed in CD38sup +CD39sup -sIgMsup - mature B cells. We demonstrate here, using in situ hybridization, that A-myb expression is restricted to the dark zone of human tonsils and lymph nodes. Furthermore, we show that A-Myb expression is cell cycle regulated both in tonsillar B cells and in Burkitt's **lymphoma** cell lines, being detectable only in the S and Ginf 2/M phases of the cell cycle and not in Ginf 0/Ginf 1 phase. Strong proliferation of resting human B cells induced in vitro by a variety of

physiologic signals, including anti-mu, **CD40 ligand**, IL-2, IL-4, IL-6, IL-13, IFN-gamma, TNF-alpha, anti-CD19, and anti-CD20, failed to induce A-myb expression, suggesting that proliferation alone is not sufficient for A-myb expression in the absence of induction of a true centroblast phenotype. Finally, we show that differentiation of germinal center B cells in vitro toward either memory or plasma cells is accompanied by rapid down-regulation of A-myb expression. We conclude that A-myb is a marker of centroblasts generated in vivo.

4/7/6 (Item 1 from file: 155)
DIALOG(R) File 155: MEDLINE(R)
(c) format only 2001 Dialog Corporation. All rts. reserv.

10810756 99458734 PMID: 10528154
1999 keystone symposium on B lymphocyte biology and disease: B cell malignancy II session.
Levy R
Division of Oncology, M 207 Stanford Medical Center, Stanford, CA, USA.
levy@leland.stanford.edu
Biochimica et biophysica acta (NETHERLANDS) Oct 29 1999, 1424 (2-3)
pR43-4, ISSN 0006-3002 Journal Code: AOW
Languages: ENGLISH
Document type: Congresses
Record type: Completed
Record Date Created: 19991208

4/7/7 (Item 1 from file: 399)
DIALOG(R) File 399: CA SEARCH(R)
(c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

134365708 CA: 134(26)365708x PATENT
Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
INVENTOR(AUTHOR): Hanna, Nabil; Hariharan, Kandasamy
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: PCT International ; WO 0134194 A1 DATE: 20010517
APPLICATION: WO 2000US30426 (20001106) *US 435992 (19991108)
PAGES: 52 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: A61K-039/395A;
A61K-051/10B; A61P-035/02B DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU;
AZ; BA; BB; BG; BR; BY; BZ; CA; CH; CN; CR; CU; CZ; DE; DK; DM; DZ; EE; ES;
FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC;
LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NO; NZ; PL; PT; RO;
RU; SD; SE; SG; SI; SK; SL; TJ; TM; TR; TT; TZ; UA; UG; UZ; VN; YU; ZA; ZW;
AM; AZ; BY; KG; KZ; MD; RU; TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW;
MZ; SD; SL; SZ; TZ; UG; ZW; AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR;
IE; IT; LU; MC; NL; PT; SE; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR;
NE; SN; TD; TG
SECTION:
CA215003 Immunochemistry
CA201XXX Pharmacology
CA208XXX Radiation Biochemistry
IDENTIFIERS: antitumor B cell CD40L antibody CD20 chemotherapy,
radiotherapy B cell tumor CD40L CD20 antibody
DESCRIPTORS:
Signal transduction, biological...
antagonism of CD40-CD40L interaction in treatment of B-cell malignancies
Radionuclides...
antibodies labeled with; for combination therapy of B-cell malignancies
CD40(antigen)...
antibodies or antibody fragments to CD40 ligand for inhibition of

signaling by
 Antitumor agents...
 B-cell leukemia; antibodies or antibody fragments to CD40 ligand
 Antitumor agents...
 B-cell lymphoma; antibodies or antibody fragments to CD40 ligand
 Antibodies...
 bispecific; to CD40 ligand for treatment of CD40+ malignancies
 Calcium channel...
 CD20; treatment of CD40+ malignancies with anti-CD40L antagonists and
 antibodies to
 Glycoproteins, specific or class...
 CD40-L (antigen CD40 ligand); treatment of CD40+ malignancies with
 antibodies or antibody fragments to
 Antibodies...
 chimeric; to CD40 ligand for treatment of CD40+ malignancies
 Alkylating agents, biological... Anthracyclines...
 for combination therapy of B-cell malignancies
 Immunoglobulins...
 fragments; to CD40 ligand for treatment of CD40+ malignancies
 Antitumor agents...
 Hodgkin's disease inhibitors; antibodies or antibody fragments to CD40
 ligand
 Antibodies...
 humanized; to CD40 ligand for treatment of CD40+ malignancies
 Radiotherapy...
 in combination with anti-CD40L antagonists for treatment of B-cell
 malignancies
 Hodgkin's disease...
 inhibitors; antibodies or antibody fragments to CD40 ligand
 Antibodies...
 monoclonal, labeled; to CD40 ligand for treatment of CD40+ malignancies
 Antibodies...
 monoclonal; to CD40 ligand for treatment of CD40+ malignancies
 Antitumor agents...
 non-Hodgkin's lymphoma; antibodies or antibody fragments to CD40 ligand
 Antibodies...
 to CD40 ligand for treatment of CD40+ malignancies
 CD20 (antigen)...
 treatment of CD40+ malignancies with anti-CD40L antagonists and
 antibodies to
 Alkaloids, biological studies...
 vinca; for combination therapy of B-cell malignancies
 CAS REGISTRY NUMBERS:
 120-73-0 analog; for combination therapy of B-cell malignancies
 10043-66-0D 10098-91-6D 13981-25-4D 14158-31-7D 14265-75-9D
 14378-26-8D 14391-11-8D 14391-96-9D 14596-37-3D 14913-49-6D
 14913-89-4D 14981-64-7D 14998-63-1D 15092-94-1D 15715-08-9D
 15750-15-9D 15755-39-2D 15757-86-5D 15766-00-4D 15776-20-2D
 31918-08-8D antibodies labeled with, biological studies, for
 combination therapy of B-cell malignancies
 50-02-2 50-18-0 51-75-2 53-03-2 57-22-7 58-05-9 59-05-2 147-94-4
 154-93-8 305-03-3 459-86-9 671-16-9 865-21-4 1247-42-3 2068-78-2
 3778-73-2 4291-63-8 4342-03-4 9015-68-3 11056-06-7 13010-47-4
 15663-27-1 18883-66-4 21679-14-1 23214-92-8 25316-40-9 29069-24-7
 33419-42-0 53910-25-1 65271-80-9 71486-22-1 for combination therapy
 of B-cell malignancies
 252662-47-8 for treatment of CD40+ malignancies
 174722-31-7D radiolabeled, in combination with anti-CD40L antagonists for
 treatment of B-cell malignancies

4/7/8 (Item 2 from file: 399)
 DIALOG(R) File 399:CA SEARCH(R)
 (c) 2001 AMERICAN CHEMICAL SOCIETY. All rts. reserv.

133149142 CA: 133(11)149142v PATENT
Production of tetravalent antibodies
INVENTOR(AUTHOR): Braslawsky, Gary Ronald; Hanna, Nabil; Hariharan,
Kandasamy; Labarre, Michael J.; Huynh, Tri B.
LOCATION: USA
ASSIGNEE: Idec Pharmaceuticals Corporation
PATENT: PCT International ; WO 200044788 A1 DATE: 20000803
APPLICATION: WO 2000US1893 (20000128) *US 238741 (19990128)
PAGES: 65 pp. CODEN: PIXXD2 LANGUAGE: English CLASS: C07K-016/00A;
C07K-016/28B; C07K-016/46B; A61K-039/395B; A61P-035/00B; A61P-035/02B;
A61P-037/00B DESIGNATED COUNTRIES: AE; AL; AM; AT; AU; AZ; BA; BB; BG; BR;
BY; CA; CH; CN; CR; CU; CZ; DE; DK; DM; EE; ES; FI; GB; GD; GE; GH; GM; HR;
HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA;
MD; MG; MK; MN; MW; MX; NO; NZ; PL; PT; RO; RU; SD; SE; SG; SI; SK; SL; TJ;
TM; TR; TT; TZ; UA; UG; US; UZ; VN; YU; ZA; ZW; AM; AZ; BY; KG; KZ; MD; RU;
TJ; TM DESIGNATED REGIONAL: GH; GM; KE; LS; MW; SD; SL; SZ; TZ; UG; ZW; AT
; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LU; MC; NL; PT; SE; BF;
BJ; CF; CG; CI; CM; GA; GN; GW; ML; MR; NE; SN; TD; TG
SECTION:
CA215003 Immunochemistry
IDENTIFIERS: antibody dimer CD20 CD23 tumor allergy, autoimmune disease
antibody dimer CD20 CD23
DESCRIPTORS:
Dermatitis...
allergic, contact; prodn. of tetravalent antibodies specific to CD20 or
CD23 for treatment of cancer, allergy or autoimmune disease
Nose...
allergic rhinitis; prodn. of tetravalent antibodies specific to CD20 or
CD23 for treatment of cancer, allergy or autoimmune disease
Asthma... Lung,disease...
allergic; prodn. of tetravalent antibodies specific to CD20 or CD23 for
treatment of cancer, allergy or autoimmune disease
Aspergillus...
aspergillosis from, allergic bronchopulmonary; prodn. of tetravalent
antibodies specific to CD20 or CD23 for treatment of cancer, allergy or
autoimmune disease
Dermatitis...
atopic; prodn. of tetravalent antibodies specific to CD20 or CD23 for
treatment of cancer, allergy or autoimmune disease
Lymphoma...
B-cell; prodn. of tetravalent antibodies specific to CD20 or CD23 for
treatment of cancer, allergy or autoimmune disease
Drug delivery systems...
carriers; prodn. of tetravalent antibodies specific to CD20 or CD23 for
treatment of cancer, allergy or autoimmune disease
Leukemia...
chronic lymphocytic; prodn. of tetravalent antibodies specific to CD20
or CD23 for treatment of cancer, allergy or autoimmune disease
Intestine,disease...
Crohn's; prodn. of tetravalent antibodies specific to CD20 or CD23 for
treatment of cancer, allergy or autoimmune disease
Antibodies...
dimer; prodn. of tetravalent antibodies specific to CD20 or CD23 for
treatment of cancer, allergy or autoimmune disease
Lymphocyte...
effector cell, cytotoxic; prodn. of tetravalent antibodies specific to
CD20 or CD23 for treatment of cancer, allergy or autoimmune disease
Immunoglobulins...
G, dimer; prodn. of tetravalent antibodies specific to CD20 or CD23 for
treatment of cancer, allergy or autoimmune disease
Glycoproteins,specific or class...
gp39; prodn. of tetravalent antibodies specific to CD20 or CD23 for
treatment of cancer, allergy or autoimmune disease
Immunoglobulins...
heavy chains, dimer; prodn. of tetravalent antibodies specific to CD20

or CD23 for treatment of cancer, allergy or autoimmune disease

Immunoglobulin receptors...

IgE type II; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

Immunoglobulins...

IgG dimer; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

Immunoglobulin receptors...

IgG; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

Immunoglobulins...

light chains, dimer; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

Functional groups...

maleimido; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

Antibodies...

monoclonal, dimer; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

Allergy... Antitumor agents... Apoptosis... Autoimmune disease...

CD20(antigen)... Complement... Crosslinking agents... Disulfide group...

DNA sequences... DNA... Epitopes... Food allergy... Graves' disease...

Lymphocyte... Neoplasm... Protein sequences... Sulfhydryl group...

prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

Functional groups...

pyridinyl group, dithio-; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

CAS REGISTRY NUMBERS:

286970-13-6P 286970-14-7 amino acid sequence; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

52-90-4 biological studies, prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

541-59-3 bis-; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease

286970-11-4P 286970-12-5 nucleotide sequence; prodn. of tetravalent antibodies specific to CD20 or CD23 for treatment of cancer, allergy or autoimmune disease